UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

~~May 24,~~October ~~2007~~2, 2009

Date of Report (Date of earliest event reported)

Avantogen Oncology, Inc.

(Exact name of registrant as specified in its charter)

Nevada	33-55254-28	87-0438641
(State or Other Jurisdiction	(Commission File Number)	(IRS Employer
of Incorporation)		Identification Number)

~~2121~~530 South ~~Avenue~~Lake ~~of the Stars~~Avenue, ~~Suite 2550~~#363, ~~Los Angeles~~Pasadena, ~~California~~CA ~~90067~~91101

(Address of Principal Executive Offices) (Zip Code)

~~310~~917-~~277~~969-~~2077~~4681

(Registrant’s telephone number, including area code)

~~N/A~~ 2121 Avenue of the Stars, Suite 2550, Los Angeles, California 90067

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 ~~CFR 240~~CFR240.14a-12)

o	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Section 1 8 - ~~Registrant’s~~Other ~~Business and Operations~~Events

Item 18.0201. ~~Termination of~~ Other ~~a Material Definitive Agreement~~Events.

AsOn ~~a result~~October 2, of2009, ~~registrant~~the Company’s ~~decision~~licensing ~~not to pursue the development and commercialization of one of the products in its portfolio~~partner, ~~INOC-005, a new~~SciClone ~~chemical entity to treat prostate cancer~~Pharmaceuticals, onInc. ~~May 24, 2007, registrant and Prostagenics LLC~~ (“~~Prostagenics~~SciClone”), announced the ~~company~~discontinuation ~~from~~of ~~which registrant obtained~~ the ~~patent~~randomized, ~~rights to INOC~~placebo-~~005~~controlled, ~~entered into a Termination of Agreement and~~ ~~Releases~~double-blind ~~dated~~Phase as2 oftrial ~~May~~that ~~18,~~evaluated ~~2007~~RP101—a ~~(the~~nucleoside ~~“Agreement”).~~analog ~~The~~known ~~Agreement terminated~~ as ofBVdU—for ~~April 5, 2007 (~~the ~~“Effective~~treatment ~~Date”)~~of ~~that~~late-stage ~~certain~~pancreatic ~~Assignment~~cancer. The ~~and Assumption~~Company ~~Agreement~~is ~~effective~~currently ~~March~~evaluating ~~31,~~next ~~2005 among registrant~~steps, ~~Prostagenics~~pending ~~and~~a ~~Gardant Pharmaceuticals,~~detailed ~~Inc.~~review ~~(the “Assignment Agreement”) pursuant to which Prostagenics assigned to registrant all of its rights~~ and ~~obligations~~analysis ~~in and under the NYMC License (as defined in the Assignment Agreement) granting Prostagenics an exclusive license covering certain rights relating to the use~~ of ~~1-nitro-9-alkylamino~~safety ~~acridine derivatives~~ and ~~1-nitroacridine/tumor~~efficacy ~~inhibitor compositions~~once ~~for~~data ~~the~~are ~~treatment~~unblinded offrom ~~cancer,~~SciClone. A ~~along with certain Prostagenics~~press ~~Confidential~~release ~~Information and agreements with consultants related to such rights. As~~ of the ~~Effective~~parent ~~Date~~company of ~~the~~Avantogen ~~Agreement~~Oncology, ~~all rights granted under the Assignment Agreement to~~Inc., ~~and all obligations assumed under the Assignment Agreement by~~Acuvax, ~~registrant reverted to Prostagenics~~Inc. ~~Pursuant to the Agreement~~, ~~Prostagenics~~ ~~and registrant also exchanged mutual general releases related~~is ~~to all~~attached ~~claims~~as ~~arising~~Exhibit ~~out of the Assignment Agreement~~10. 1.

~~The~~Item ~~Agreement is filed as Exhibit 10~~9.101 toFinancial ~~this~~Statements ~~Form 8-K~~ and ~~is incorporated into this Item 1~~Exhibits.02 by reference. The foregoing description of such document does not purport to be complete and is qualified in its entirety by reference to the full text of such document.

Section 9 - Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

The following exhibit is filed with this report:


Exhibit No.		Exhibit

10.1		Press Release of Acuvax, Inc./Avantogen Oncology, Inc. dated October 5, 2009

10.1 Termination of Agreement and Releases dated as of May 18, 2007 between Prostagenics LLC and Avantogen Oncology, Inc.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Avantogen Oncology, Inc. By: /s/ ~~Angela~~William ~~Bronow~~Ardrey ~~Davanzo~~William ~~Angela~~Ardrey ~~Bronow Davanzo~~ Chief ~~Financial~~Executive Officer

Date: ~~May 31~~October 9, ~~2007~~2009

EXHIBIT INDEX

10.1 Termination of Agreement and Releases dated as of May 18, 2007 between Prostagenics LLC and Avantogen Oncology, Inc.

Exhibit No.		Exhibit

10.1		Press Release of Acuvax, Inc./Avantogen Oncology, Inc. dated October 5, 2009

Filing Compare · Avantogen Oncology, Inc.